TM Owner Coherus Oncology, Inc.
Loqtorzi IV 240mg/6ml Injection (solution, single-dose vial)
Global Shipping : Reliable Global Distribution Network
Express Delivery : Priority Shipping for Every Order
Secure Payments : Trusted Payment Protection System
Disclaimer
Secure Handling
24/7 Worldwide Support
Global Access
Worldwide Access to Health
Cold-Chain Expert
Excellence in Cold-Chain
Trusted Supply
Certified Medical Supply
Indications & Clinical Uses
- Loqtorzi IV is the same medicine as Loqtorzi: toripalimab-tpzi, a PD-1-blocking monoclonal antibody supplied as a single-dose vial of 240 mg in 6 mL (40 mg/mL) that is diluted and given as an intravenous infusion by a healthcare professional.
- This catalogue row duplicates the Loqtorzi entry; there is no separate product called Loqtorzi IV.
- In the United States it is approved with cisplatin and gemcitabine for first-line treatment of adults with metastatic or recurrent locally advanced nasopharyngeal carcinoma, and alone for adults with recurrent unresectable or metastatic nasopharyngeal carcinoma that has progressed on or after platinum-containing chemotherapy.
- The EU authorisation adds first-line oesophageal squamous cell carcinoma with cisplatin and paclitaxel.
- Dosing is 240 mg every three weeks in combination, or 3 mg/kg every two weeks alone, in a hospital or clinic only.
Side Effects
- Given with cisplatin and gemcitabine, toripalimab-tpzi most often causes nausea (71%), vomiting (68%), loss of appetite (55%), constipation (39%), an underactive thyroid (38%) and rash (36%).
- As a single agent the leading reactions are tiredness (22%), underactive thyroid (20%) and musculoskeletal pain (20%).
- There is no boxed warning on the US label.
- The important risks are immune-mediated: the antibody can trigger inflammation in the lungs (pneumonitis), bowel (colitis), liver (hepatitis), hormone glands (thyroid disease, adrenal insufficiency, hypophysitis, new diabetes), kidneys, skin, heart (myocarditis) and nerves.
- Contact the oncology team the same day about a new cough or breathlessness, watery or bloody diarrhoea, yellow eyes, severe fatigue, chest pain, palpitations, muscle weakness, excessive thirst or a spreading rash, including after treatment has finished.
Precautions & Warnings
- This is a concentrate for intravenous infusion: it must be diluted before use and never given as an intravenous bolus or push.
- The first infusion runs over 60 minutes; if that is tolerated, later infusions may run over 30 minutes.
- Only a specialist team experienced with immune checkpoint inhibitors should prescribe it, and thyroid, liver, kidney and glucose tests are taken at baseline and repeated during treatment.
- Immune-mediated reactions are managed by withholding the antibody and starting corticosteroids; severe organ inflammation may require permanent discontinuation.
- Tell the team about autoimmune disease, a previous organ or stem cell transplant, or ongoing immunosuppressants.
- Effective contraception is required during treatment and for four months after the final dose, and breastfeeding is not recommended.
- Unopened vials are refrigerated at 2°C to 8°C; do not freeze or shake.
Avoid Interactions
- No formal drug-interaction studies are reported in the US prescribing information and the label carries no drug-interaction section, because toripalimab-tpzi is a monoclonal antibody cleared by protein breakdown rather than liver enzymes, so CYP-mediated interactions are not expected.
- Practical cautions still apply.
- Systemic corticosteroids or other immunosuppressants taken before starting may blunt the intended immune response, although steroids are the correct treatment once an immune-mediated reaction develops, so never adjust them yourself.
- Live vaccines are generally avoided while on checkpoint-inhibitor therapy; ask the oncology team before any vaccination.
- Report all prescription medicines, over-the-counter products, herbal remedies and supplements, particularly anything that can injure the liver.
- In the pharmacy, dilute only as directed, give through a line without mixing other medicines, and do not freeze.
References
Frequently Asked Questions
Loqtorzi IV (toripalimab-tpzi) is the same product as Loqtorzi and treats nasopharyngeal carcinoma in adults: with cisplatin and gemcitabine as first-line therapy, or alone after platinum chemotherapy. The EU label adds first-line oesophageal squamous cell carcinoma. It is a PD-1 blocking antibody.
Loqtorzi IV (toripalimab-tpzi) comes as a 240 mg in 6 mL vial that the pharmacy dilutes for intravenous infusion. The combination dose is 240 mg every three weeks; used alone it is 3 mg/kg every two weeks. It must never be injected as a rapid bolus or push.
With chemotherapy, Loqtorzi IV (toripalimab-tpzi) commonly causes nausea, vomiting, poor appetite, constipation, an underactive thyroid and rash. Because it activates the immune system it can inflame the lungs, bowel, liver, hormone glands, kidneys, skin, heart or nerves. Report new cough, diarrhoea or yellow eyes the same day.
Avoid live vaccines during Loqtorzi IV (toripalimab-tpzi) treatment unless the oncology team agrees, and never start or stop steroids or herbal supplements yourself. Pregnancy must be avoided: use effective contraception during treatment and for four months after the last dose. Do not breastfeed.
Thyroid function, liver enzymes, kidney function and blood glucose are checked before Loqtorzi IV (toripalimab-tpzi) starts and repeated during treatment, because immune-mediated side effects often appear on blood tests first. The team reviews symptoms at every visit and uses scans to judge the cancer response.
The first Loqtorzi IV (toripalimab-tpzi) infusion runs over 60 minutes; if there was no reaction, later infusions may be given over 30 minutes. Staff watch for fever, chills, flushing, rash or breathlessness throughout. The diluted solution is used within 8 hours at room temperature.
Trusted & Reliable – Your Partner in Global Distribution.
We provide comprehensive lines of pharmaceutical products to support all your healthcare distribution needs.
